These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Diarrhoea with the angiotensin receptor neprilysin inhibitor sacubitril + valsartan: A pharmacovigilance study. Guion-Firmin J; Tessier S; Lepelley M; Faillie JL; Montastruc JL Fundam Clin Pharmacol; 2022 Apr; 36(2):378-389. PubMed ID: 34260768 [TBL] [Abstract][Full Text] [Related]
7. Evolution of functional class, biochemical and echocardiographic parameters and clinical outcomes after sacubitril/valsartan initiation in daily practice. Morillas-Climent H; Seller-Moya J; Vicedo-López Á; Galcerá-Jornet E; Alania-Torres E; Rodríguez-Pichardo Y; Larumbe-Rodríguez A; Valle-Muñoz A J Comp Eff Res; 2019 Jul; 8(9):685-697. PubMed ID: 31290687 [No Abstract] [Full Text] [Related]
8. ▼ Sacubitril valsartan for heart failure. Drug Ther Bull; 2016 Jun; 54(6):66-9. PubMed ID: 27284124 [TBL] [Abstract][Full Text] [Related]
9. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP; N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794 [TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of sacubitril-valsartan: a systematic review and meta-analysis. Martins E Pereira G; S Duarte G; Katerenchuk V; Costa J; David C; Ferreira JJ; Pinto FJ; Caldeira D Expert Opin Drug Saf; 2021 May; 20(5):577-588. PubMed ID: 33459086 [No Abstract] [Full Text] [Related]
11. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Böhm M; Young R; Jhund PS; Solomon SD; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Packer M; McMurray JJV Eur Heart J; 2017 Apr; 38(15):1132-1143. PubMed ID: 28158398 [TBL] [Abstract][Full Text] [Related]
12. Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction. McCormack PL Drugs; 2016 Mar; 76(3):387-96. PubMed ID: 26873495 [TBL] [Abstract][Full Text] [Related]
13. Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization. Langenickel TH; Jordaan P; Petruck J; Kode K; Pal P; Vaidya S; Chandra P; Rajman I Eur J Clin Pharmacol; 2016 Aug; 72(8):917-24. PubMed ID: 27083930 [TBL] [Abstract][Full Text] [Related]
14. Real-World Prevalence of Adverse Events After Initiating Sacubitril/Valsartan Compared With Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Systolic Heart Failure. Adie S; Bitar A; Hanigan S; Pogue K; Koelling T; Dorsch M J Card Fail; 2019 May; 25(5):412-413. PubMed ID: 30904558 [No Abstract] [Full Text] [Related]
15. Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study. Shi V; Senni M; Streefkerk H; Modgill V; Zhou W; Kaplan A Int J Cardiol; 2018 Aug; 264():118-123. PubMed ID: 29776559 [TBL] [Abstract][Full Text] [Related]
16. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936 [TBL] [Abstract][Full Text] [Related]
17. Life Threatening Angioedema Due to Valsartan/Sacubitril With Previously Well-Tolerated ACE Inhibitor. Raheja H; Kumar V; Kamholz S; Hollander G; Shani J Am J Ther; 2018; 25(4):e508-e509. PubMed ID: 28452844 [No Abstract] [Full Text] [Related]
18. Sacubitril/Valsartan is useful and safe in elderly people with heart failure and reduced ejection fraction. Data from a real-word cohort. Esteban-Fernández A; Díez-Villanueva P; Vicent L; Bover R; Gómez-Bueno M; De Juan J; Iniesta ÁM; García-Aguado M; Martínez-Sellés M Rev Esp Geriatr Gerontol; 2020; 55(2):65-69. PubMed ID: 31892433 [TBL] [Abstract][Full Text] [Related]
19. Sacubitril/Valsartan and Mexiletine: A Proarrhythmic Combination? Weir RAP Cardiology; 2019; 142(1):4-6. PubMed ID: 30852576 [TBL] [Abstract][Full Text] [Related]
20. Sacubitril/Valsartan-Associated Small Bowel Ileus. Hanefeld-Fox L; Jimenez L; Heflin R; Quiel L Am J Ther; 2018; 25(6):e705-e706. PubMed ID: 29324464 [No Abstract] [Full Text] [Related] [Next] [New Search]